Towards cure of CML: Why we need to know more about CML stem cells?

Current Stem Cell Research and Therapy

Volumn 4, Issue 3, 2009, Pages 224-236

  Janssen, Jeroen J W M ^a   Schuurhuis, Gerrit J ^a   Terwijn, Monique ^a   Ossenkoppele, Gerrit J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CML; Immunophenotyping; Signal transduction; Stem cells; Tyrosine kinase inhibitors

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; 6 BROMOINDIRUBIN 3 OXIME; ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DIMETHYLAMINOPARTHENOLIDE; ETOPOSIDE; HYDROXYUREA; IMATINIB; INDIRUBIN; JANUS KINASE; LONAFARNIB; MERBARONE; NILOTINIB; PARTHENOLIDE; PEPTIDE VACCINE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL ADHESION; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; CYTOGENETICS; DEPRESSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; NONHUMAN; PALLIATIVE THERAPY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 74849084634     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488809789057428     Document Type: Review

References (207)

1. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol 2000; 110: 2-11.
2. Nowell P, Hungerford D. A minute chromosome in human granulocytic leukemia. Science 1960; 132: 1497.
3. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-3.
4. Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med 1985; 313: 1429-33.
5. Ben Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212-4.
6. th ed. Churchill Livingstone 2008; pp. 1247-52.
7. Bartram CR. Rearrangement of the c-abl and bcr genes in Phnegative CML and Ph-positive acute leukemias. Leukemia 1988; 2: 63-4.
8. Kantarjian HM, Shtalrid M, Kurzrock R, et al. Significance and correlations of molecular analysis results in patients with Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia. Am J Med 1988; 85: 639-44.
9. Wiedemann LM, Karhi KK, Shivji MK, et al. The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseases. Blood 1988; 71: 349-55.
10. Bertazzoni U, Brusamolino E, Isernia P, et al. Prognostic significance of terminal transferase and adenosine deaminase in acute and chronic myeloid leukemia. Blood 1982; 60: 685-92.
11. Beard M, Gauci C, Sikora E, et al. Blast crisis of chronic myeloid leukaemia: the effect of intensive chemotherapy. Scand J Haematol 1976; 16: 258-62.
12. Iacoboni SJ, Plunkett W, Kantarjian HM, et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986; 4:1079-88.
13. Muehleck SD, McKenna RW, Arthur DC, Parkin JL, Brunning RD. Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. Am J Clin Pathol 1984; 82: 1-14.
14. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-17.
15. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809-20.
16. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-6.
17. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111: 1834-9.
18. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or highdose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007; 109: 5143-50.
19. Cortes J, Bruemmendorf T, Kantarjian H, et al. Efficacy and safety of Bosutinib (SKI-606) among patients with chronic phase Ph+ Chronic Myelogenous Leukemia (CML). ASH Annu Meet Abstr 2007; 110: 733.
20. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCRABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615-9.
21. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009; 23: 477-85.
22. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469-71.
23. Horowitz MM, Rowlings PA. An update from the international bone marrow transplant registry and the autologous blood and marrow transplant registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 1997; 4: 395-400.
24. Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reducedintensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456-3462.
25. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reducedintensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-76.
26. The Benelux CML Study Group. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia. Bone Marrow Transplant 1996; 17(Suppl 3): S19-S20.
27. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-5.
28. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392-1397.
29. Ohnishi K, Ohno R, Tomonaga M, et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-16.
30. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-77.
31. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-9.
32. Haferlach T, Winkemann M, Nickenig C, et al. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 1997; 97: 99-106.
33. Garicochea B, Chase A, Lazaridou A, Goldman JM. T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients. Leukemia 1994; 8: 1197-201.
34. Whang J, Frei E, Tjio JH, Carbone PP, Brecher G. The distribution of the philadelphia chromosome in patients with chronic myelogenous leukemia. Blood 1963; 22: 664-73.
35. Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 1998; 92: 4758-63.
36. Radhika V, Thennarasu S, Naik NR, et al. Granulocytes from chronic myeloid leukemia (CML) patients show differential response to different chemoattractants. Am J Hematol 1996; 52: 155-64.
37. Wolach B, Gavrieli R, Manor Y, Lishner M. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis 1998; 24: 544-51.
38. Udomsakdi C, Eaves CJ, Swolin B, et al. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192-6.
39. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 1990, 87: 3584-8.
40. Dooley DC, Law P. Detection and quantitation of long-term culture-initiating cells in normal human peripheral blood. Exp Hematol 1992; 20: 156-60.
41. Eaves CJ, Cashman JD, Zoumbos NC, Barnett MJ, Eaves AC. Biological strategies for the selective manipulation of normal and leukemic stem cells. Stem Cells 1993; 11 Suppl 3: 109-21.
42. Eaves C, Cashman J, Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res 1998; 22: 1085-96.
43. Shapiro HM. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and pyronin Y. Cytometry 1981; 2:143-150.
44. Huttmann A, Liu SL, Boyd AW, Li CL. Functional heterogeneity within rhodamine123(lo) Hoechst33342(lo/sp) primitive hemopoietic stem cells revealed by pyronin Y. Exp Hematol 2001; 29: 1109-16.
45. Habibian HK, Peters SO, Hsieh CC, et al. The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J Exp Med 1998; 188: 393-8.
46. Gothot A, van der Loo JC, Clapp DW, Srour EF. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Blood 1998; 92: 2641-9.
47. Glimm H, Oh IH, Eaves CJ. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 2000; 96: 4185-93.
48. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056-64.
49. Ponchio L, Conneally E, Eaves C. Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood 1995; 86: 3314-21.
50. Holyoake TL, Jiang X, Jorgensen HG, et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001; 97: 720-8.
51. Udomsakdi C, Eaves CJ, Lansdorp PM, Eaves AC. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 1992; 80: 2522-30.
52. Douville J, Beaulieu R, Balicki D. ALDH1 as a Functional Marker of Cancer Stem and Progenitor Cells. Stem Cells Dev 2008. [Epub ahead of print].
53. Cheung AM, Wan TS, Leung JC, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21: 1423-30.
54. Bao F, Polk P, Nordberg ML, et al. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res 2007; 31: 1511-20.
55. Dick JE, Bhatia M, Gan O, Kapp U, Wang JC. Assay of human stem cells by repopulation of NOD/SCID mice. Stem Cells 1997; 15(Suppl) 1: 199-203.
56. Eisterer W, Jiang X, Christ O, et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 19: 435-41.
57. van Rhenen A, Moshaver B, Kelder A, et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21: 1700-07.
58. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCIDrepopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 1996; 87: 1539-48.
59. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-67.
60. Abrahamsson A, Geron I, Gotlib J, et al. Epigenetic alteration of GSK3beta expression in chronic myelogenous leukemia stem cells [abstract]. American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA); 2007. Abstract no. 1318 2008.
61. de Groot RP, Coffer PJ, Koenderman L. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal 1998; 10: 619-28.
62. de Groot RP, Raaijmakers JAM, Lammers JW, Koenderman L. STAT5-dependent cyclind1 and Bcl-xL expression in Bcr-Abltransformed cells. Mol Cell Biol Res Commun 2000; 3: 299-305.
63. Matsumura I, Kitamura T, Wakao H, et al. Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J. 1999, 18: 1367-77.
64. Huang M, Dorsey JF, Epling-Burnette PK, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene 2002; 21: 8804-16.
65. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 1998; 83: 724-32.
66. Miyakawa Y, Oda A, Druker BJ, et al. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996; 87: 439-46.
67. Mandanas RA, Boswell HS, Lu L, Leibowitz D. BCR/ABL confers growth factor independence upon a murine myeloid cell line. Leukemia 1992; 6: 796-800.
68. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 1993; 21: 1460-6.
69. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887-95.
70. Shuai K, Halpern J, Ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13: 247-54.
71. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-20.
72. Ilaria RL, Jr., Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271: 31704-10.
73. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000; 19: 2523-31.
74. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science 1995; 269: 1875-7.
75. Coppo P, Dusanter-Fourt I, Millot G, et al. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 2003; 22: 4102-10.
76. Ahmed M, Dusanter-Fourt I, Bernard M, et al: BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 1998; 16: 489-96.
77. Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996; 10: 1724-30.
78. Zhang G, Fu Y. Antiproliferative effect of indomethacin on CML cells is related to the suppression of STATs/Bcl-XL signal pathway. Ann Hematol 2006; 85: 443-9.
79. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159:4720-8.
80. Xie S, Wang Y, Liu J, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001; 20: 6188-95.
81. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006; 66: 6468-72.
82. Hariharan IK, Adams JM, Cory S. Bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 1988; 3: 387-99.
83. Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575-85.
84. Anderson SM, Mladenovic J. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion. Blood 1996; 87: 238-244.
85. Li S, Gillessen S, Tomasson MH, et al. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 2001; 97: 1442-50.
86. Wong S, McLaughlin J, Cheng D, et al. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proc Natl Acad Sci USA 2003; 100: 11630-5.
87. Jiang X, Ng E, Yip C, et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 2002; 100: 3731-40.
88. Sattler M, Salgia R, Okuda K, et al. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene 1996; 12: 839-46.
89. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993; 75: 175-85.
90. Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 2000; 96: 664-70.
91. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764-73.
92. Kardinal C, Konkol B, Lin H, et al. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood 2001; 98: 1773-81.
93. Pelicci G, Lanfrancone L, Salcini AE, et al. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 1995; 11: 899-907.
94. Patel H, Marley SB, Gordon MY. Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes Cancer 2006; 45: 1121-29.
95. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hema topoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 1994; 179: 167-75.
96. Cortez D, Reuther G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997; 15: 2333-42.
97. Gong R, Rifai A, Ge Y, Chen S, Dworkin LD. Hepatocyte growth factor suppresses proinflammatory NFkappaB activation through GSK3beta inactivation in renal tubular epithelial cells. J Biol Chem 2008; 283: 7401-10.
98. Deng J, Xia W, Miller SA, et al. Crossregulation of NF-kappaB by the APC/GSK-3β/β-catenin pathway. Mol Carcinog 2004; 39: 139-46.
99. De Toni F, Racaud-Sultan C, Chicanne G, et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006; 25: 3113-22.
100. Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
101. Ress A, Moelling K. Bcr is a negative regulator of the Wnt signalling pathway. EMBO Rep 2005; 6: 1095-100.
102. Coluccia AM, Vacca A, Dunach M, et al. Bcr-Abl stabilizes ??-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007; 26: 1456-66.
103. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12.
104. Oda T, Heaney C, Hagopian JR, et al. Crkl is the major tyrosinephosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925-8.
105. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005; 65: 2047-53.
106. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Baddependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000; 20: 1179-86.
107. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 2000; 96: 2269-76.
108. Kuribara R, Honda H, Matsui H et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004; 24: 6172-83.
109. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436-44.
110. Aichberger KJ, Mayerhofer M, Krauth MT, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-11.
111. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003; 22: 9007-21.
112. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992; 90: 1232-41.
113. Jongen-Lavrencic M, Salesse S, Delwel R, Verfaillie CM: BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells. Leukemia 2005; 19: 373-80.
114. Dhut S, Chaplin T, Young BD. Normal c-abl gene protein - a nuclear component. Oncogene 1991; 6: 1459-64.
115. Wetzler M, Talpaz M, Van Etten RA, et al. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993; 92: 1925-39.
116. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 1995; 270: 21468-71.
117. Sattler M, Salgia R: Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia 1998; 12: 637-644.
118. Bhat A, Kolibaba K, Oda T, et al. Interactions of CBL with BCRABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem 1997; 272: 16170-5.
119. Salgia R, Sattler M, Pisick E, Li JL, Griffin JD. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol 1996; 24: 310-3.
120. Salgia R, Brunkhorst B, Pisick E, et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 1995; 11: 1149-55.
121. Walker JL, Fournier AK, Assoian RK: Regulation of growth factor signaling and cell cycle progression by cell adhesion and adhesiondependent changes in cellular tension. Cytokine Growth Factor Rev 2005; 16: 395-405.
122. Jiang Y, Prosper F, Verfaillie CM. Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors. Blood 2000; 95: 846-54.
123. Zhao C, Blum J, Chen A, et al. Loss of β-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528-41.
124. Holmes T, O'Brien TA, Knight R, et al. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 2008; 26: 1288-97.
125. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on hedgehog pathway activation. Cancer Cell 2008; 14: 238-49.
126. Trowbridge JJ, Xenocostas A, Moon RT, Bhatia M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 2006; 12: 89-98.
127. Campbell C, Risueno RM, Salati S, Guezguez B, Bhatia M. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Curr Opin Hematol 2008; 15: 319-25.
128. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 2006; 20: 537-9.
129. Bai LY, Chiu CF, Lin CW, et al. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies. Leukemia 2008; 22: 226-8.
130. Sawa M, Yamamoto K, Yokozawa T, et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005; 82: 42-7.
131. Raaphorst FM. Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene Bmi-1. Trends Immunol 2003; 24: 522-4.
132. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-60.
133. Hosen N, Yamane T, Muijtjens M, et al. Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells. Stem Cells 2007; 25: 1635-44.
134. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-3.
135. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-8.
136. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
137. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002; 20: 11-20.
138. Bradford GB, Williams B, Rossi R, Bertoncello I. Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol 1997; 25: 445-53.
139. Abkowitz JL, Golinelli D, Harrison DE, Guttorp P. In vivo kinetics of murine hemopoietic stem cells. Blood 2000; 96: 3399-405.
140. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci USA 1999; 96: 3120-5.
141. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-35.
142. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-9.
143. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926-35.
144. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low
145. OCT-1 activity. Blood 2007; 110: 4064-72. [145] White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704.
146. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370-3.
147. Bewry NN, Nair RR, Emmons MF, et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169-75.
148. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002; 107:76-94.
149. Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000; 95: 1883-90.
150. Brummendorf TH, Rufer N, Holyoake TL, et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann N Y Acad Sci 2001; 938: 293-303.
151. Boultwood J, Fidler C, Shepherd P, et al. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. Am J Hematol 1999; 61: 5-9.
152. Campbell LJ, Fidler C, Eagleton H, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006; 20: 671-9.
153. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 6783-7.
154. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 2002; 30: 48-58.
155. Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107: 2507-16.
156. Bi S, Lanza F, Goldman JM. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res 1994; 54:582-6.
157. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003; 3: 145-60.
158. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995; 85: 2013-6.
159. Karasawa M, Okamoto K, Maehara T, et al. Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes. Leuk Res 1996; 20: 85-91.
160. Tedeschi FA, Zalazar FE: HOXA9 gene expression in the chronic myeloid leukemia progression. Leuk Res 2006; 30: 1453-6.
161. Strathdee G, Holyoake TL, Sim A, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 2007; 13: 5048-55.
162. Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res 2007; 31: 1521-8.
163. Agirre X, Roman-Gomez J, Vazquez I, et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 2006; 118: 1945-53.
164. Nagy E, Beck Z, Kiss A, et al. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer 2003; 39: 2298-305.
165. Liu TC, Lin SF, Chang JG, et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 2003; 123: 654-61.
166. Hernandez-Boluda JC, Cervantes F, Colomer D, et al. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol 2003; 31: 204-10.
167. Asimakopoulos FA, Shteper PJ, Krichevsky S, et al ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999; 94: 2452-60.
168. Mills KI, Guinn BA, Walsh VA, Burnett AK. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leuk Res 1996; 20: 771-5.
169. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: Increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008; 270: 1-9.
170. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717-23.
171. Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.
172. Sallmyr A, Tomkinson AE, Rassool FV: Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. Blood 2008; 112: 1413-23.
173. Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008; 68: 2576-80.
174. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-12.
175. Jorgensen HG, Copland M, Allan EK, et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006; 12: 626-33.
176. Holtz M, Forman SJ, Bhatia R: Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007; 67: 1113-20.
177. Konig H, Hartel N, Schultheis B, et al. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells. Haematologica 2007; 92: 838-41.
178. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30: 729-37.
179. Saad SY, Alkharfy KM, Arafah MM: Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol 2006; 58: 567-73.
180. Jorgensen HG, Allan EK, Graham SM, et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 2005; 19: 1184-91.
181. Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843-53.
182. Cortes J, Jabbour E, Daley GQ, et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007; 110: 1295-1302.
183. Borthakur G, Kantarjian H, Daley G, et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006; 106: 346-52.
184. Deenik W, van der HB, Verhoef GE, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 111: 2581-8.
185. Deenik W, van der HB, Verhoef GE, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility and efficacy in newly diagnosed patients with chronic myeloid leukaemia. Blood 2008; 111: 2581-8.
186. Mikami I, You L, He B, et al. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC.Cancer 2005; 5: 53.
187. He B, You L, Uematsu K, et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004; 6: 7-14.
188. Huang L, Shitashige M, Satow R, et al. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Gastroenterology 2007; 133: 1569-78.
189. Guzman ML, Li X, Corbett CA, et al. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007; 110: 4436-44.
190. Oki Y, Kantarjian HM, Gharibyan V, et al. Phase II study of lowdose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899-906.
191. Kantarjian HM, O'Brien S, Cortes J, et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522-8.
192. Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert.Opin.Investig. Drugs 2003; 12: 1985-93.
193. Du Y, Wang K, Fang H, et al. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 2006; 107: 1582-90.
194. Yin T, Wu YL, Sun HP, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004; 104: 4219-25.
195. La Rosee P, Johnson K, Corbin AS, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004; 103: 208-15.
196. Nimmanapalli R, Bali P, O'Bryan E, et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Cancer Res 2003; 63: 7950-8.
197. La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002; 30: 729-37.
198. Arunasree KM, Roy KR, Anilkumar K, et al. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res 2008; 32: 855-64.
199. Zhang GS, Liu DS, Dai CW, Li RJ: Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 2006; 81: 242-55.
200. Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003; 88: 853-63.
201. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005; 105: 4163-9.
202. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007; 110: 4427-35.
203. Bocchia M, Korontsvit T, Xu Q, et al. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-92.
204. Bocchia M, Wentworth PA, Southwood S, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680-4. [205] Schmitt M, Li L, Giannopoulos K, et al. Chronic myeloid leukemia
205. cells express tumor-associated antigens eliciting specific CD8+ Tcell responses and are lacking costimulatory molecules. Exp Hematol 2006; 34: 1709-19.
206. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657-62.
207. van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 2007; 110: 2659-66.